ECSP19053616A - N-[4-fluoro-5-[[(2s,4s)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il)metoxi]-1-piperidil]metil]tiazol-2-il]acetamida como inhibidor de oga - Google Patents

N-[4-fluoro-5-[[(2s,4s)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il)metoxi]-1-piperidil]metil]tiazol-2-il]acetamida como inhibidor de oga

Info

Publication number
ECSP19053616A
ECSP19053616A ECSENADI201953616A ECDI201953616A ECSP19053616A EC SP19053616 A ECSP19053616 A EC SP19053616A EC SENADI201953616 A ECSENADI201953616 A EC SENADI201953616A EC DI201953616 A ECDI201953616 A EC DI201953616A EC SP19053616 A ECSP19053616 A EC SP19053616A
Authority
EC
Ecuador
Prior art keywords
methyl
metoxy
oxadiazol
thiazol
piperidyl
Prior art date
Application number
ECSENADI201953616A
Other languages
English (en)
Inventor
Peter James Lindsay-Scott
Nicolas Jacques Francois Dreyfus
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP19053616A publication Critical patent/ECSP19053616A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona un compuesto de Fórmula I o una sal farmacéuticamente aceptable del mismo, y el uso de compuestos de Fórmula I para el tratamiento de enfermedades y trastornos neurodegenerativos, tales como la enfermedad de Alzheimer.
ECSENADI201953616A 2017-01-27 2019-07-26 N-[4-fluoro-5-[[(2s,4s)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il)metoxi]-1-piperidil]metil]tiazol-2-il]acetamida como inhibidor de oga ECSP19053616A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762451137P 2017-01-27 2017-01-27

Publications (1)

Publication Number Publication Date
ECSP19053616A true ECSP19053616A (es) 2019-08-30

Family

ID=61157343

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201953616A ECSP19053616A (es) 2017-01-27 2019-07-26 N-[4-fluoro-5-[[(2s,4s)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il)metoxi]-1-piperidil]metil]tiazol-2-il]acetamida como inhibidor de oga

Country Status (36)

Country Link
US (1) US10081625B2 (es)
EP (1) EP3573983B1 (es)
JP (1) JP6738970B2 (es)
KR (1) KR102275338B1 (es)
CN (1) CN110198940B (es)
AR (1) AR110747A1 (es)
AU (1) AU2018213029B2 (es)
CA (1) CA3049141C (es)
CL (1) CL2019001978A1 (es)
CO (1) CO2019007711A2 (es)
CR (1) CR20190320A (es)
CY (1) CY1124257T1 (es)
DK (1) DK3573983T3 (es)
DO (1) DOP2019000187A (es)
EA (1) EA038368B1 (es)
EC (1) ECSP19053616A (es)
ES (1) ES2871949T3 (es)
HR (1) HRP20211011T1 (es)
HU (1) HUE054990T2 (es)
IL (1) IL267693B (es)
JO (1) JOP20190182B1 (es)
LT (1) LT3573983T (es)
MA (1) MA47368B1 (es)
MD (1) MD3573983T2 (es)
MX (1) MX2019008846A (es)
MY (1) MY197494A (es)
PE (1) PE20191406A1 (es)
PH (1) PH12019501707A1 (es)
PL (1) PL3573983T3 (es)
PT (1) PT3573983T (es)
RS (1) RS61979B1 (es)
SI (1) SI3573983T1 (es)
TW (1) TWI654978B (es)
UA (1) UA123472C2 (es)
WO (1) WO2018140299A1 (es)
ZA (1) ZA201904171B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6563017B2 (ja) 2014-08-28 2019-08-21 エースニューロン・ソシエテ・アノニム グリコシダーゼ阻害剤
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
EP3419971B1 (en) 2016-02-25 2022-04-20 Asceneuron SA Glycosidase inhibitors
KR20180132060A (ko) 2016-02-25 2018-12-11 아셰뉴론 에스아 피페라진 유도체의 산 부가 염
MX2018010191A (es) 2016-02-25 2019-05-20 Asceneuron S A Inhibidores de glucosidasa.
AR111693A1 (es) 2017-05-25 2019-08-07 Lilly Co Eli Compuestos de 5-metil-1,3,4-oxadiazol-2-ilo con actividad inhibitoria de oga
EP3672959A1 (en) 2017-08-24 2020-07-01 Asceneuron SA Linear glycosidase inhibitors
TWI726329B (zh) 2018-06-22 2021-05-01 美商美國禮來大藥廠 2,3-二氫呋喃并[2,3-b]吡啶化合物
CN112469476B (zh) * 2018-07-31 2024-07-16 伊莱利利公司 5-甲基-4-氟-噻唑-2-基化合物
EP3829634A1 (en) * 2018-07-31 2021-06-09 Eli Lilly and Company Combination therapy
WO2020039029A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Spiro compounds as glycosidase inhibitors
US12016852B2 (en) 2018-08-22 2024-06-25 Asceneuron Sa Pyrrolidine glycosidase inhibitors
WO2020039028A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Tetrahydro-benzoazepine glycosidase inhibitors
KR20210060513A (ko) * 2018-09-19 2021-05-26 바이오젠 엠에이 인코포레이티드 O-당단백질-2-아세트아미도-2-데옥시-3-d-글루코피라노시다제 억제제
TWI716107B (zh) 2018-09-26 2021-01-11 美商美國禮來大藥廠 6-氟-2-甲基苯并[d]噻唑-5-基化合物
JP2022510430A (ja) * 2018-12-05 2022-01-26 バイオジェン・エムエイ・インコーポレイテッド モルホリニル、ピペラジニル、オキサゼパニル及びジアゼパニルｏ－糖タンパク質－２－アセトアミド－２－デオキシ－３－ｄ－グルコピラノシダーゼ阻害剤
WO2020163193A1 (en) * 2019-02-04 2020-08-13 Biogen Ma Inc. Bicyclic ether o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
WO2021094312A1 (en) 2019-11-11 2021-05-20 Janssen Pharmaceutica Nv Pyrrolidine and bicycloheteroaryl containing oga inhibitor compounds
WO2021110656A1 (en) 2019-12-02 2021-06-10 Janssen Pharmaceutica Nv Oga inhibitor compounds
CA3160367A1 (en) 2019-12-18 2021-06-24 Jose Manuel Bartolome-Nebreda Oga inhibitor compounds
CA3160405A1 (en) 2019-12-18 2021-06-24 Jose Manuel Bartolome-Nebreda Oga inhibitor compounds
WO2021123291A1 (en) 2019-12-18 2021-06-24 Janssen Pharmaceutica Nv Oga inhibitor compounds
AR123031A1 (es) * 2020-07-23 2022-10-26 Lilly Co Eli Régimen de dosis baja y formulación de un compuesto 5-metil-1,2,4-oxadiazol-3-ilo
BR112023002013A2 (pt) 2020-08-03 2023-05-02 Biogen Ma Inc Formas cristalinas de um inibidor de o-glicoproteína-2-acetamido-2-desóxi-3-d-glucopiranosidase
KR20240099297A (ko) * 2021-10-22 2024-06-28 일라이 릴리 앤드 캄파니 O-GlcNAcase (OGA) 억제제 조합 요법
IL314657A (en) 2022-02-03 2024-09-01 Lilly Co Eli TAU regional imaging for the diagnosis and treatment of Alzheimer's disease
WO2024083820A1 (en) 2022-10-18 2024-04-25 Institut National de la Santé et de la Recherche Médicale Method and composition for determining the level of o-glcnacylation in horses

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8726763D0 (en) 1987-11-16 1987-12-23 Fujisawa Pharmaceutical Co Thiazole compounds
CN1777584A (zh) 2003-04-18 2006-05-24 伊莱利利公司 作为5－ht1f激动剂的(哌啶氧基)苯基、(哌啶氧基)吡啶基、(哌啶硫基)苯基和(哌啶硫基)吡啶基化合物
SE0302116D0 (sv) 2003-07-21 2003-07-21 Astrazeneca Ab Novel compounds
CA2634250A1 (en) * 2005-12-21 2007-07-05 Schering Corporation Phenoxypiperidines and analogs thereof useful as histamine h3 antagonists
EP2139332A4 (en) * 2007-03-28 2010-04-21 Merck Sharp & Dohme SUBSTITUTED PYRIDO [2,3-D] PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS
TWI431004B (zh) * 2008-05-02 2014-03-21 Lilly Co Eli Ｂａｃｅ抑制劑
EP2569291B1 (en) 2010-05-11 2016-04-06 Simon Fraser University Selective glycosidase inhibitors and uses thereof
AU2014241065B2 (en) * 2013-03-14 2017-08-31 Merck Patent Gmbh Glycosidase inhibitors
WO2014192868A1 (ja) * 2013-05-30 2014-12-04 大日本住友製薬株式会社 環状アミノメチルピリミジン誘導体
JP6563017B2 (ja) * 2014-08-28 2019-08-21 エースニューロン・ソシエテ・アノニム グリコシダーゼ阻害剤
WO2017106254A1 (en) 2015-12-18 2017-06-22 Merck Sharp & Dohme Corp. Glycosidase inhibitors and uses thereof
EP3555087A1 (en) * 2016-12-16 2019-10-23 Janssen Pharmaceutica NV Monocyclic oga inhibitor compounds

Also Published As

Publication number Publication date
US20180215751A1 (en) 2018-08-02
CR20190320A (es) 2019-08-27
US10081625B2 (en) 2018-09-25
CL2019001978A1 (es) 2019-12-13
EP3573983A1 (en) 2019-12-04
IL267693A (en) 2019-08-29
ZA201904171B (en) 2022-01-26
WO2018140299A1 (en) 2018-08-02
IL267693B (en) 2021-08-31
LT3573983T (lt) 2021-07-26
MA47368B1 (fr) 2021-07-29
TWI654978B (zh) 2019-04-01
MY197494A (en) 2023-06-19
MD3573983T2 (ro) 2021-10-31
KR102275338B1 (ko) 2021-07-12
PL3573983T3 (pl) 2021-10-04
PT3573983T (pt) 2021-06-17
HRP20211011T1 (hr) 2021-09-17
RS61979B1 (sr) 2021-07-30
JP6738970B2 (ja) 2020-08-12
JP2020504142A (ja) 2020-02-06
ES2871949T3 (es) 2021-11-02
EA201991515A1 (ru) 2020-01-16
EA038368B1 (ru) 2021-08-17
CO2019007711A2 (es) 2019-07-31
DK3573983T3 (da) 2021-06-28
JOP20190182B1 (ar) 2023-03-28
CN110198940B (zh) 2022-09-23
TW201836607A (zh) 2018-10-16
AU2018213029B2 (en) 2020-11-05
EP3573983B1 (en) 2021-04-21
CY1124257T1 (el) 2022-07-22
JOP20190182A1 (ar) 2019-07-25
MX2019008846A (es) 2019-09-10
PE20191406A1 (es) 2019-10-04
NZ754849A (en) 2021-10-29
PH12019501707A1 (en) 2020-03-16
KR20190096421A (ko) 2019-08-19
HUE054990T2 (hu) 2021-10-28
CA3049141A1 (en) 2018-08-02
CN110198940A (zh) 2019-09-03
DOP2019000187A (es) 2019-08-15
UA123472C2 (uk) 2021-04-07
SI3573983T1 (sl) 2021-08-31
AR110747A1 (es) 2019-05-02
CA3049141C (en) 2021-02-16
BR112019013535A2 (pt) 2020-01-07
AU2018213029A1 (en) 2019-07-04

Similar Documents

Publication Publication Date Title
ECSP19053616A (es) N-[4-fluoro-5-[[(2s,4s)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il)metoxi]-1-piperidil]metil]tiazol-2-il]acetamida como inhibidor de oga
AR111693A1 (es) Compuestos de 5-metil-1,3,4-oxadiazol-2-ilo con actividad inhibitoria de oga
CY1121062T1 (el) Φαρμακευτικες συνθεσεις για την αντιμετωπιση της νοσου alzheimer
PE20151542A1 (es) Compuestos de tetrahidropirrolotiazina
DOP2019000010A (es) Compuesto (r)-n-(5-cloro-1-(3,3-difluoro-1-(oxetan-3-il)piperidin-4-il)-1h-pirazol-4-il)-4-etoxi-7h-pirrolo[2,3-d]pirimidin-2-amina o sal farmacéuticamente aceptable del mismo
AR103680A1 (es) Inhibidores selectivos de bace1
PE20141824A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
CO2017001875A2 (es) Terapia de combinación contra el alzheimer usando anticuerpos anti-n3pglu más un inhibidor bace
EA201791802A1 (ru) СШИТЫЕ ДИГИДРО-4H-ПИРАЗОЛО[5,1-c][1,4]ОКСАЗИНИЛОВЫЕ СОЕДИНЕНИЯ И АНАЛОГИ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЦНС
MY174747A (en) Bace1 inhibitors
UY37837A (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
CO2018001383A2 (es) Derivados de n-[piridin-4-il]metil]-4-{(1r)-1-[(3s)-3-metil-2,5-dioxopirrolidin-3-il]etil}benzamida como antagonistas del receptor cgrp”
PH12019500569A1 (en) Blood-brain barrier-penetrant dopamine-b-hydroxylase inhibitors
CU24434B1 (es) Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1
EA201692298A1 (ru) Производные карбоксамидов
CO2019013254A2 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
CL2017002229A1 (es) Inhibidores de bace1.
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
DOP2017000240A (es) Derivados de aminohidrotiazina fusionados con tetrahidrofurano los cuales son útiles en el tratamiento de la enfermedad de alzheimer
EA202190359A1 (ru) Способы лечения нейродегенеративных расстройств
CO2020001375A2 (es) Derivado de adamantilmetilamina y uso del mismo como producto farmacéutico
CO2017000019A2 (es) Forma polimórfica novedosa del clorhidrato de n-[2-(6-fluoro-1h-indol-3-il)etil]-3-(2,2,3,3-tetrafluoropropoxi)bencilamina para el tratamiento del alzhéimer
AR115865A2 (es) Compuestos terapéuticos
CU20160170A7 (es) Derivados de carboxamida
TH167631B (th) วิธีการบำบัดโรคอัลไซเมอร์และองค์ประกอบทางเภสัชกรรมของมัน